Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Noens

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Acta Clinica Belgica|December 3, 2014
Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing surveyY Beguin, D Selleslag, S Meers, et al.
Acta Clinica Belgica|February 4, 2009
Guidelines for the transfusion of red cellsP L Baele, L Muylle, L Noens, et al.
Acta Clinica Belgica|November 8, 2014
Myelofibrosis patients in Belgium: disease characteristicsT Devos, P Zachée, D Bron, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Acta Clinica Belgica|December 3, 2014
Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing surveyY Beguin, D Selleslag, S Meers, et al.
Acta Clinica Belgica|February 4, 2009
Guidelines for the transfusion of red cellsP L Baele, L Muylle, L Noens, et al.
Acta Clinica Belgica|November 8, 2014
Myelofibrosis patients in Belgium: disease characteristicsT Devos, P Zachée, D Bron, et al.
Pageof 4